Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on May 14, 2016 - 03:23 GMT

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C virus (HCV) clinical development programs at the …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2016 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple tumor types, both as …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 30 scientific data presentations on the company’s established and investigational …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, May 5. …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy ...

KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head, the company’s comparative, Phase 3, open-label clinical trial evaluating the …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’ …

Distribution channels: Companies

Published on May 14, 2016 - 03:23 GMT

Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin), and new real- …

Distribution channels: Companies

Published on January 5, 2016 - 13:14 GMT

Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on …

Distribution channels: Companies

Published on January 4, 2016 - 13:01 GMT

Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck’s chairman and chief executive officer, is scheduled to participate at the Goldman Sachs Healthcare CEOs …

Distribution channels: Companies

Published on December 23, 2015 - 13:31 GMT

World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G …

Distribution channels: Companies

Published on December 19, 2015 - 15:56 GMT

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to …

Distribution channels: Companies

Published on December 18, 2015 - 21:16 GMT

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA® (pembrolizumab), the company’s anti- …

Distribution channels: Companies

Published on December 18, 2015 - 13:02 GMT

Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company’s …

Distribution channels: Companies

Published on December 17, 2015 - 23:18 GMT

Merck’s BRIDION® (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION® (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL …

Distribution channels: Companies

Published on December 15, 2015 - 22:50 GMT

FDA Approves Expanded Age Indication for GARDASIL® 9 in Males

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL®9 (Human Papillomavirus 9-valent …

Distribution channels: Companies

Published on December 14, 2015 - 23:25 GMT

Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to …

Distribution channels: Companies